aTyr Pharma Stock Forecast, Price & News

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

Is aTyr Pharma a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" aTyr Pharma stock.
View analyst ratings for aTyr Pharma or view top-rated stocks.

How has aTyr Pharma's stock price been impacted by Coronavirus?

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LIFE stock has increased by 166.0% and is now trading at $8.06.
View which stocks have been most impacted by COVID-19.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a drop in short interest during the month of October. As of October 29th, there was short interest totaling 793,800 shares, a drop of 34.4% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 5,350,000 shares, the short-interest ratio is currently 0.1 days.
View aTyr Pharma's Short Interest.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for aTyr Pharma.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) released its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.11. During the same quarter in the prior year, the company posted ($0.68) earnings per share.
View aTyr Pharma's earnings history.

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

Shares of aTyr Pharma reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for LIFE?

7 equities research analysts have issued 12 month price targets for aTyr Pharma's stock. Their forecasts range from $11.00 to $22.00. On average, they anticipate aTyr Pharma's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 123.3% from the stock's current price.
View analysts' price targets for aTyr Pharma or view top-rated stocks among Wall Street analysts.

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the following people:

• Sanjay S. Shukla, President, Chief Executive Officer & Director (LinkedIn Profile)
• Jill M. Broadfoot, Chief Financial Officer
• Leslie Nangle, Vice President-Research
• Andrew B. Cubitt, Vice President-External Scientific Alliances
• Ashlee Dunston, Director-Investor Relations & Communications

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma CEO Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among aTyr Pharma's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of aTyr Pharma's key competitors?

Some companies that are related to aTyr Pharma include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Waters (WAT), Charles River Laboratories International (CRL), Bio-Techne (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and BG Medicine (BGMD).
View all of LIFE's competitors.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include VR Adviser LLC (9.25%), Tang Capital Management LLC (6.58%), Two Sigma Investments LP (3.20%), Two Sigma Advisers LP (2.85%), Stonepine Capital Management LLC (2.43%) and EAM Investors LLC (1.54%). Company insiders that own aTyr Pharma stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends for aTyr Pharma.

Which institutional investors are selling aTyr Pharma stock?

LIFE stock was sold by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C., BlackRock Inc., and Millennium Management LLC. Company insiders that have sold aTyr Pharma company stock in the last year include Jill Marie Broadfoot, John K Clarke, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma or view top insider-selling stocks.

Which institutional investors are buying aTyr Pharma stock?

LIFE stock was acquired by a variety of institutional investors in the last quarter, including VR Adviser LLC, Tang Capital Management LLC, Two Sigma Investments LP, Stonepine Capital Management LLC, Two Sigma Advisers LP, EAM Investors LLC, Citadel Advisors LLC, and EAM Global Investors LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, Paul Schimmel, and Sanjay Shukla.
View insider buying and selling activity for aTyr Pharma or or view top insider-buying stocks.

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $8.06.

How much money does aTyr Pharma make?

aTyr Pharma has a market capitalization of $224.00 million and generates $10.45 million in revenue each year. The biotechnology company earns $-16.22 million in net income (profit) each year or ($2.04) on an earnings per share basis.

How many employees does aTyr Pharma have?

aTyr Pharma employs 42 workers across the globe.

When was aTyr Pharma founded?

aTyr Pharma was founded in 2005.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is www.atyrpharma.com.

Where are aTyr Pharma's headquarters?

aTyr Pharma is headquartered at 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 731-8389, via email at [email protected], or via fax at 858-731-8394.